Welcome to the
NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease (PD), some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.
Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page, or for more PD-focused content, check out our disease spotlight on Parkinson disease.
Episode Breakdown:
1:20 – Lingering unmet needs in Parkinson disease management
3:10 – The advances in identifying therapeutic targets in PD
4:25 – Bridging the gap to more effective long-term treatment
6:00 – Overview of IPX203 and its potential to treat PD
7:45 – Neurology News Minute
10:15 – Possible advantages of IPX203
13:25 – Safety profile of IPX203 in clinical development
15:50 – The importance of addressing dose-wearing off
16:40 – Closing thoughts
This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023!
Nominate: neurologylive.com/Giants-of-MS
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Thanks for listening to the
NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit
neurologylive.com.
